^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    exoASO-C/EBPβ

    i
    Other names: exoASO-C/EBPβ, exoASO-C/EBPB
    Associations

    News

    Trials
    Company:
    Codiak
    Drug class:
    CEBPB antagonist
    Related drugs:
    Associations

    News

    Trials
    almost4years
    Exosome-mediated delivery of antisense oligonucleotides targeting C/EBPβ reprograms tumor-associated macrophages and induces potent single agent anti-tumor activity (AACR 2022)
    exoASO-C/EBPβ is a novel therapeutic candidate that selectively targets and attenuates a critical transcription factor in immunosuppressive myeloid cells, resulting in reprogramming of TAMs and potent anti-tumor activity across multiple TAM-rich mouse models as a monotherapy.
    PD(L)-1 Biomarker • IO biomarker
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • CSF1R (Colony stimulating factor 1 receptor) • ITGAM (Integrin, alpha M) • MRC1 (Mannose Receptor C-Type 1) • NOS2 (Nitric Oxide Synthase 2)
    |
    exoASO-C/EBPβ